CDX
VCaP
Tumor indication
Prostate
Tumor subtype
Prostate carcinoma
Description
VCaP (Prostate Cancer CDX Model)
The VCaP prostate cancer line was derived from a vertebral bone metastasis of prostate carcinoma. It is androgen receptor–positive and expresses prostate-specific antigen (PSA). VCaP carries the TMPRSS2-ERG gene fusion, a frequent alteration in prostate cancer. Its biology provides strong translational relevance for AR-driven research.
Key Features:
- Derived from vertebral metastasis of prostate cancer.
- Androgen receptor–positive, PSA-expressing.
- Contains TMPRSS2-ERG gene fusion.
- Tumorigenic in xenografts.
Applications:
VCaP is applied in studies of androgen receptor signaling and therapeutic development. Researchers use it to evaluate anti-androgen and combination therapies. It supports biomarker research, particularly involving ERG fusions. Its metastasis-derived biology makes it valuable in advanced prostate cancer pipelines.
Details
- Tumor indication
- Prostate
- Tumor subtype
- Prostate carcinoma
- Organism
- Human
- Mouse sex
- Male
- Lumin data
- Proteomics
Mutated genes
Select a gene to see the variants recorded for this line.
Gene expression
Show all values
| Gene | Expression |
|---|
Expression measured across the Champions panel.
Lumin data
Request this cell line
Let's build the right study, together.
Backed by deep expertise in these models, our team will work with you to design the study around your target, line of therapy, and endpoint.